Your search returned 3 results.

Results
	1.	Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs. [electronic resource] by Xu, Peng Tong, Ying Liu, Xiu-zhen Wang, Ting-ting Cheng, Li Wang, Bo-yu Lv, Xiang Huang, Yue Liu, De-pei Producer: 20160726 In: Scientific reports vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. [electronic resource] by Cao, Ling Yang, Yong-Jing Diao, Jian-Dong Zhang, Xu-He Liu, Yan-Ling Wang, Bo-Yu Li, Zhi-Wen Liu, Shi-Xin Publication details: Oncotarget Oct 2017 In: Oncotarget vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. [electronic resource] by Cao, Ling Yang, Yong-Jing Diao, Jian-Dong Zhang, Xu-He Liu, Yan-Ling Wang, Bo-Yu Li, Zhi-Wen Liu, Shi-Xin Publication details: Oncotarget 08 2018 In: Oncotarget vol. 9 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search